XML 30 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (14,487,132) $ (5,462,047)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of deferred financing fees   129
Amortization of debt discount   396
Stock-based compensation expense, including stock issued to consultants and advisors 4,697,627 1,864,913
Change in fair value of derivative liability   26,500
Changes in operating assets and liabilities:    
Grant receivable   735,075
Prepaid expenses and other current assets (270,788) (34,097)
Accounts payable 346,218 (695,660)
Accrued expenses 581,916 (406,032)
Net cash used in operating activities (9,132,159) (3,970,823)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 46,648,413 12,034,406
Proceeds from exercise of stock options 95,102 9,217
Net cash provided by financing activities 46,743,515 12,043,623
Net increase in cash and cash equivalents 37,611,356 8,072,800
Cash and cash equivalents, beginning of year 8,074,658 1,858
Cash and cash equivalents, end of year $ 45,686,014 8,074,658
Supplemental disclosure of non-cash financing activities:    
Conversion of redeemable convertible preferred stock to common stock   7,076,952
Conversion of convertible promissory notes, including embedded derivative, to common stock   $ 672,524